Therapeutics that discriminate between the genetic makeup of normal cells and tumour cells are valuable for treating and understanding cancer. Small molecules with oncogene-selective lethality may reveal novel functions of oncoproteins and enable the creation of more selective drugs 1 . Here we describe the mechanism of action of the selective anti-tumour agent erastin, involving the RAS-RAF-MEK signalling pathway functioning in cell proliferation, differentiation and survival. Erastin exhibits greater lethality in human tumour cells harbouring mutations in the oncogenes HRAS, KRAS or BRAF. Using affinity purification and mass spectrometry, we discovered that erastin acts through mitochondrial voltage-dependent anion channels (VDACs)-a novel target for anti-cancer drugs. We show that erastin treatment of cells harbouring oncogenic RAS causes the appearance of oxidative species and subsequent death through an oxidative, non-apoptotic mechanism. RNA-interference-mediated knockdown of VDAC2 or VDAC3 caused resistance to erastin, implicating these two VDAC isoforms in the mechanism of action of erastin. Moreover, using purified mitochondria expressing a single VDAC isoform, we found that erastin alters the permeability of the outer mitochondrial membrane. Finally, using a radiolabelled analogue and a filter-binding assay, we show that erastin binds directly to VDAC2. These results demonstrate that ligands to VDAC proteins can induce non-apoptotic cell death selectively in some tumour cells harbouring activating mutations in the RAS-RAF-MEK pathway.
Therapeutics that discriminate between the genetic makeup of normal cells and tumour cells are valuable for treating and understanding cancer. Small molecules with oncogene-selective lethality may reveal novel functions of oncoproteins and enable the creation of more selective drugs 1 . Here we describe the mechanism of action of the selective anti-tumour agent erastin, involving the RAS-RAF-MEK signalling pathway functioning in cell proliferation, differentiation and survival. Erastin exhibits greater lethality in human tumour cells harbouring mutations in the oncogenes HRAS, KRAS or BRAF. Using affinity purification and mass spectrometry, we discovered that erastin acts through mitochondrial voltage-dependent anion channels (VDACs)-a novel target for anti-cancer drugs. We show that erastin treatment of cells harbouring oncogenic RAS causes the appearance of oxidative species and subsequent death through an oxidative, non-apoptotic mechanism. RNA-interference-mediated knockdown of VDAC2 or VDAC3 caused resistance to erastin, implicating these two VDAC isoforms in the mechanism of action of erastin. Moreover, using purified mitochondria expressing a single VDAC isoform, we found that erastin alters the permeability of the outer mitochondrial membrane. Finally, using a radiolabelled analogue and a filter-binding assay, we show that erastin binds directly to VDAC2. These results demonstrate that ligands to VDAC proteins can induce non-apoptotic cell death selectively in some tumour cells harbouring activating mutations in the RAS-RAF-MEK pathway.
In a screen of about 24,000 compounds, we discovered erastin, which induces rapid death in engineered human tumour cells (BJ-TERT/LT/ST/RAS V12 cells, ref.
2) with oncogenic v-Ha-ras Harvey rat sarcoma viral oncogene homologue (HRAS)
V12 , but not in isogenic, non-tumorigenic cells lacking oncogenic RAS (BJ-TERT/LT/ ST cells) (Fig. 1a, Supplementary Fig. 1 and ref. 3). This cell death was not dependent on the rate of cell division, nor was it idiosyncratic to these cells ( Fig. 1a and Supplementary Fig. 2 ), because cell lines engineered in a similar way responded similarly.
We found that erastin-treated cells did not display changes in nuclear morphology characteristic of apoptosis (Fig. 1c, ref. 3). However, imaging by electron microscopy did reveal changes in mitochondrial morphology, such as loss of structural integrity (Fig. 1b) . These mitochondrial morphological changes were not observed in response to staurosporine, hydrogen peroxide or rapamycin-compounds that induce apoptosis, necrosis and autophagy, respectively (Fig. 1b and data not shown).
Given that erastin is a new compound found in a cell-based screen, we had no insight into its mechanism of action. We used a two-pronged approach to define the mechanism, involving, first, a suppressor screen to identify annotated compounds that prevent erastin-induced cell death and, second, an affinity purification approach to identify proteins that mediate the activity of erastin. First, we performed a suppressor screen using a library of about 2,000 biologically active compounds 4 and found that antioxidants (a-tocopherol, butylated hydroxytoluene and b-carotene) prevent erastin-induced death (Fig. 1d, Supplementary Fig. 3 ). Moreover, we detected generation of an oxidizing species in response to erastin treatment in BJ-TERT/LT/ST/RAS V12 cells, but not in isogenic BJ-TERT cells (Fig. 1e, Supplementary Fig. 4 ). Finally, we found that erastin-induced death in the HT-1080 fibrosarcoma cell line was also suppressed by antioxidants ( Supplementary Fig. 5 ).
To characterize the mode of erastin-induced cell death, we looked for features of well characterized death pathways. We determined that the oxidizing species generated in BJ-TERT/LT/ST/RAS V12 cells in the presence of erastin emanate from mitochondria (see Supplementary Discussion), consistent with the perturbation in mitochondrial morphology. We discovered that the oxidizing species do not cause poly(ADP ribose) polymerase 1 (PARP1) cleavage (Fig. 1f , Supplementary Fig. 6 ), cytochrome c release from mitochondria ( Fig. 1g) , or pro-caspase-3 cleavage (Fig. 1h) 3,5,6 -all of which are hallmarks of apoptosis, a stereotypical form of cell death activated by many antitumour agents 3, [7] [8] [9] [10] as well as by staurosporine ( Fig. 1f-h ). Moreover, we looked for these hallmarks in four different cell lines sensitive to erastin; none showed activation of these markers (Fig. 1f, h ). Other canonical hallmarks of apoptosis were similarly absent (see Supplementary Information). In summary, these initial studies revealed that erastin induces rapid, oxidative, non-apoptotic death in tumour cells with oncogenic HRAS.
To define the genetic basis of the selective lethality of erastin, we used a lentiviral-based RNA interference system 11 . We originally discovered erastin in a screen for oncogenic-HRAS-selective lethal compounds. However, v-Ki-ras2 Kirsten rat sarcoma viral oncogene homologue (KRAS) is more frequently mutated in human cancers than HRAS 12 . Selective toxicity in mutant-KRAS-expressing cell lines would broaden the applicability of erastin as a therapeutic. Thus, we tested whether erastin was selectively lethal to tumour cells harbouring oncogenic KRAS, and whether this lethality could be arrested by knockdown of KRAS. We found that a lung carcinoma cell line (Calu-1) with an activating mutation in KRAS was sensitive to erastin (half-maximal inhibitory concentration, IC 50 5 4 mM; Table 4 ), these cells exhibited resistance to erastin (Fig. 2a, b) .
RAS proteins are known to modulate many downstream pathways, and genetic lesions in these pathways are associated with many cancer types 12 . To clarify the connection between erastin and oncogenic RAS signalling, we sought evidence that erastin acts in a manner that is specific to cells with activated RAS-RAF-MEK signalling (Supplementary Table 1 and Supplementary Discussion). One cell line with moderate sensitivity to erastin was A-673 (Supplementary Table 1) , containing an activating V600E mutation in v-raf murine sarcoma viral oncogene homologue B1 (BRAF)-a direct target of RAS 13 . To determine whether the activating mutation in BRAF influences erastin sensitivity, we created two different shRNAs targeting BRAF messenger RNA (Supplementary Table 4) . We found that A-673 cells containing either of these constructs were resistant to erastin (Fig.  2c-e) . Moreover, co-expression of a non-targetable V600E mutant BRAF partially restored sensitivity of these cells to erastin (Supplementary Fig. 7) .
To confirm that activated RAS-RAF-MEK signalling renders other tumour cells sensitive to erastin, we examined the effect of mitogenactivated protein kinase (MAPK)/extracellular signal-regulated kinase (ERK) kinase 1/2 (MEK1/2) inhibitors on erastin sensitivity. All three inhibitors caused erastin resistance in both BJ-TERT/LT/ST/RAS V12 and HT-1080 cells, with activating mutations in HRAS and NRAS, respectively ( Fig. 2f and Supplementary Fig. 8 ; Supplementary Table 2 shows the effect of these MEK inhibitors alone on cell viability). Finally, we found a modest correlation between ERK1/2 phosphorylation status and erastin sensitivity in 12 sarcoma cell lines (Table 1) . In summary, KRAS and BRAF knockdown, MEK inhibition, and analysis of ERK1/2 phosphorylation status together suggest that erastin contains a degree of selectivity for cells in which the RAS-RAF-MEK pathway is constitutively activated.
For the second prong of our approach to defining the mechanism of action of erastin (affinity-based target identification), we synthesized erastin analogues that could be linked to a solid-phase resin for biochemical purification of potential targets. We found that replacement of the p-chloro substituent in erastin with the aminomethyl group necessary for linkage to a resin resulted in an analogue (erastin A6, Fig. 2g ) that, though less potent, retained the ability to kill BJ-TERT/LT/ST/RAS V12 cells, but not BJ-TERT cells ( Supplementary  Fig. 9 ). We also identified a suitable analogue (erastin B2, Supplementary Information) that lacked activity ( Fig. 2g and Supplementary Fig. 9 ), and thus could serve as a negative control for target purification.
We immobilized erastin A6 and erastin B2 on solid-phase resin and sought proteins that interact with A6, but not B2. Using BJ-TERT/LT/ST/RAS V12 cell lysates, we identified all three isoforms of the human mitochondrial voltage-dependent anion channels (VDAC1, VDAC2 and VDAC3) on the A6 resin, but only VDAC1 on the B2 resin (Supplementary Table 3 , 7-14) . Using BJ-TERT cell lysates, we identified a small amount of VDAC1 on the A6 resin, but none of the VDACs on the B2 resin. Thus, it appears that erastin A6 isolates VDAC2 and VDAC3 more efficiently than does erastin B2. Furthermore, the finding that erastin pulls down a mitochondrial protein (VDAC) is consistent with observations that erastin induces mitochondria-driven oxidative death.
VDACs (also known as eukaryotic porins) are membranespanning channels that facilitate transmembrane transport of ions and metabolites 14, 15 , most notably across the outer mitochondrial membrane 16 . It has been demonstrated that VDACs are gated by membrane voltage, at least in vitro (Supplementary Discussion): in the closed state, ions, but not small molecule metabolites, can penetrate VDAC pores 17 ; in the open state, both ions and metabolites pass through VDAC channels. In addition, the closed state is cationselective, whereas the open state is anion-selective.
Having identified VDACs as a potential target of erastin, we sought evidence that altered expression of VDACs contributes to altered erastin sensitivity. To determine whether VDACs are upregulated in response to oncogenic HRAS, we measured VDAC abundance in the BJ cell series (see ref. 2 and Supplementary Discussion for engineering and genetics of BJ cell series). In BJ-TERT/LT/ST/RAS V12 cells, the total amount of VDAC protein is increased (Fig. 3a and Supplementary Fig. 10 ). These results suggest that erastin acts by a gainof-function mechanism, and that cells with more VDAC protein are more sensitive to erastin, although other aspects of cellular physiology may also be relevant.
Next, using two-dimensional gel electrophoresis to evaluate protein expression in BJ-TERT/LT/ST/RAS V12 cells ( Supplementary  Fig. 11 ), we found that, after 8 h of erastin treatment, VDAC3 was no longer detectable, and, after 10 h, VDAC2 became undetectable (Fig. 3b) . Doxorubicin and camptothecin are examples of agents that act by a gain-of-function mechanism on their molecular targets, topoisomerase IIa and topoisomerase I, respectively 18 . It may be that a cellular response to erastin is downregulation of VDAC2/3 after lethal oxidative species have been generated, as occurs with camptothecin and topoisomerase I following DNA damage. The fact that VDAC1 is still present at later time points suggests that the loss of VDAC2/3 is not simply caused by loss of mitochondria.
To test the gain-of-function hypothesis, we reduced VDAC protein levels using lentiviral shRNA expression 11 . We created multiple shRNA constructs targeting each VDAC isoform (Supplementary Table 4 and Supplementary Fig. 12 ) and tested their effects on cell sensitivity to erastin (Supplementary Figs 13-15) . We found that knockdown of VDAC3 caused significant resistance to erastin (Fig.  3c, d and Supplementary Fig. 15 ). We also observed some degree of The maximum percentage cell death induced by erastin in each cell line is shown, along with the level of phospho-ERK1/2 as quantified by western blot (arbitrary units). The correlation is 0.41.
erastin resistance when VDAC2 was knocked down (Fig. 3c, e and Supplementary Fig. 14) . In contrast, overexpression of VDAC3 alone in BJ-TERT cells yielded no increase in sensitivity to erastin ( Supplementary Fig. 16 ), suggesting that VDAC3, and to some degree VDAC2, is necessary but not sufficient for sensitivity to erastin and that other downstream features of RAS-RAF-MEK signalling are also needed. Overall, these results are consistent with a gain-of-function mechanism involving erastin and VDAC2/3. Furthermore, this effect is specific to erastin, and not to other lethal compounds: VDAC2-deficient embryonic stem cells have been shown to be more sensitive, not less sensitive, to staurosporine and etoposide 19 . To test the hypothesis that erastin alters mitochondrial outer membrane permeability, we monitored the function of VDACs using purified mitochondria from yeast engineered to express a single mouse VDAC isoform in place of yeast VDAC 20 . A previous report demonstrated that the rate of NADH uptake through the outer membrane of such mitochondria is dependent on the specific VDAC expressed in yeast. We found that erastin treatment yielded a decrease in the rate of NADH oxidation, suggesting a reduced permeability of these mitochondria to NADH when mouse VDAC1 or VDAC2 were expressed ( Fig. 3f and Supplementary  Fig. 17 ). We found little NADH oxidation in mitochondria expressing VDAC3, suggesting minimal intrinsic membrane permeability ( Supplementary Fig. 17) ; this is consistent with previous reports that VDAC3 does not gate well in vitro 20 . Finally, we found that an inactive analogue of erastin (erastin A8, Fig. 2g and Supplementary Fig. 9 ) had no such effect (Fig. 3f and Supplementary Fig. 17 ). These results suggest that erastin affects VDAC gating, possibly switching its ion selectivity and allowing cationic species into mitochondria.
Having demonstrated interactions between erastin and VDAC using affinity-based target identification and VDAC functional assays, we explored the direct binding of erastin to VDACs. Using modified versions of previously reported protocols, we isolated VDAC2 from Escherichia coli for use in a competition binding experiment 21, 22 using a radiolabelled analogue (erastin A9). The results demonstrate that the cold RAS-selective lethal erastin A9 (IC 50 5 1.9 mM, Supplementary Fig. 9 ), unlike inactive erastin A8, directly binds to VDAC2 (dissociation constant, K d 5 112 nM; Fig. 3g ), in the process competing off radiolabelled erastin A9.
The data presented herein are consistent with a model in which erastin interacts with VDAC proteins to induce mitochondrial dysfunction, release of oxidative species and, ultimately, non-apoptotic, oxidative cell death. This process has a degree of selectivity for cells with activated RAS-RAF-MEK signalling. These results demonstrate that it is feasible to discover oncogene-selective compounds and to use them to clarify oncogene-related cell death mechanisms.
METHODS SUMMARY
VDAC identification using pull-down assay. Erastin A6 and B2 were linked to a solid-phase resin, which was then incubated with BJ-TERT/LT/ST/RAS V12 or BJ-TERT cell lysate and washed before protein was eluted and then digested as described 23 . Reverse-phase high-performance liquid chromatography was performed before samples were analysed using both a 4700 Proteomics Analyser matrix-assisted laser desorption/ionization-time of flight (TOF)/TOF (TOF/ TOF; Applied Biosystems) and a Q Trap (AB/MDS Sciex). Tandem mass spectrometry (MS/MS) data was then compared against either the corrected NCBInr protein sequence database or the HumanNR database (http://www.ncbi.nlm. nih.gov/). GPS Explorer (Applied Biosystems) was used for submitting data acquired from the TOF/TOF for database searching. Knockdown using lentiviral shRNAs. HT-1080 and Calu-1 cells were infected with lentiviruses expressing shRNAs targeting VDAC and KRAS, respectively (Supplementary Table 4) . A-673 cells were infected with retroviruses 24 expressing shRNAs against either BRAF or luciferase (Supplementary Table 4) . NADH oxidation assay. NADH oxidation in the mitochondria was measured by resuspending mitochondria isolated from yeast in 25 mM NADH, with or without erastin, and monitoring absorbance at l 5 340 nm (ref. 20) . As a control for mitochondrial intactness, parallel assays were run using hypotonically shocked mitochondria. VDAC2 binding assay. VDAC2 protein was isolated from E. coli using a modified version of a previously described protocol 22 . To assay direct binding of erastin analogues, 40 mg of purified VDAC2 was incubated in the presence of 20 mM radiolabelled erastin A9 and serial dilutions of unlabelled erastin A9 or erastin A8. The mixture was then deposited onto a binding filter using vacuum filtration. After rinsing, radioactivity was detected on a liquid scintillation counter (LKB Wallac 1,211 RACKBETA). Full protocols. For detailed methods, which additionally include cell culture, western blotting, cell viability assays, PARP cleavage, cytochrome c release, oxidative species detection, transmission electron microscopy, VDAC3 overexpression, PCR with reverse transcription and quantitative PCR, see Methods.
Full Methods and any associated references are available in the online version of the paper at www.nature.com/nature. initiation factor 4E (eIF4E) protein ratio in engineered BJ-derived cells as quantified using western blot. b, BJ-TERT/LT/ST/RAS V12 cells were treated with erastin and harvested at indicated time points for quantitative twodimensional western blot. The top panel is an illustration of VDAC isoforms separated by two-dimensional gel electrophoresis. c, Isoform-specific knockdown of VDAC in HT-1080 cells infected with virus expressing either VDAC3-or VDAC2-targeted shRNA plasmid (shVDAC3 or shVDAC2) was confirmed using two-dimensional protein gels. d, e, These cells were then treated with erastin dilutions, and viability relative to no treatment (y axis) was determined using Trypan blue exclusion and compared to an identical process using a GFP control plasmid. f, Rate of NADH oxidation, normalized to no treatment, in mitochondria purified from VDACknockout yeast expressing murine VDAC2 was determined in the presence of erastin (red) or an inactive analogue, erastin A8 (black). g, Direct binding to VDAC2 was assayed using tritium-labelled erastin A9 in competition with unlabelled erastin A9 (red) or erastin A8 (black). All error bars in Fig. 3 represent one standard deviation, n 5 2 or 3.
METHODS
Cell culture and western blotting. BJ-TERT/LT/ST/RAS V12 cells were cultured as described in ref. 3 . Other cell lines were grown according to specifications of the American Type Culture Collection. For western blots, medium was aspirated and each dish was washed twice with 10 ml ice-cold PBS. Cells were lysed with 200 ml buffer (50 mM HEPES, 40 mM NaCl, 2 mM EDTA, 0.5% Triton-X, 1.5 mM sodium orthovanadate, 50 mM NaF, 10 mM sodium pyrophosphate, 10 mM sodium b-glycerophosphate and protease inhibitor tablet (Roche), (pH 7.4)). For one-dimensional western blots, samples were separated using SDS-polyacrylamide gel electrophoresis; for two-dimensional western blots, samples were prepared using the ZOOM IPGRunner System (Invitrogen). ) for 6, 10, 12, 12.5, 13, 14, 18 or 26 h, and prepared for western blotting. For the cytochrome c release assay, cells were washed with 10 ml ice-cold PBS, suspended in 120 ml buffer (300 mM sucrose, 0.1% BSA, 10 mM HEPES (pH 7.5), 10 mM KCl, 1.5 mM MgCl 2 , 1 mM EGTA, 1 mM EDTA, 1 mM dithiothreitol (DTT), 2 mM phenylmethanesulphonyl fluoride and one protease inhibitor tablet (Roche)) and incubated on ice for 15 min. Cells were lysed by passing them through a 25-gauge needle (5 strokes). Cell lysates were centrifuged at 400g for 5 min at 4 uC to remove the nuclear fraction. Mitochondria were removed from the soluble cytosolic fraction by pelleting at 10,500g. Supernatant and mitochondrial pellets were solubilized in SDS-polyacrylamide gel electrophoresis loading buffer and analysed by western blotting. Oxidative species detection. 2979-dichlorodihydrofluorescein diacetate (H 2 DCF-DA, Molecular Probes) was used to measure oxidative species by flow cytometry. Non-fluorescent H 2 DCF-DA was cleaved by endogenous esterases and then was oxidized to generate fluorescent DCF. BJ-TERT/LT/ST/RAS V12 and BJ-TERT cells were seeded at 3 3 10 5 cells per dish in 60 mm dishes and allowed to grow overnight. Cells were treated with 4.6 mM erastin for 2, 4, 6, 8, 10 and 12 h. For each time point, controls were maintained for untreated cells and also for positive control (treated directly with 500 mM hydrogen peroxide for 5 min). Cells were incubated with 10 mM H 2 DCF-DA for 10 min, harvested by trypsinization, washed twice with cold PBS, resuspended in 100 ml PBS and incubated with 5 ml of 50 mg ml -1 propidium iodide for 10 min. 400 ml PBS was added and the solution was analysed by flow cytometry (FACSCalibur, BectonDickinson). FL1-H indicates arbitrary units of DCF fluorescence detected. VDAC pull-downs. Cultures of BJ-TERT and BJ-TERT/LT/ST/RAS V12 cells (ten 150-mm plates) were washed with PBS, lysed in 25 mM HEPES (pH 7.5), 150 mM NaCl, 1% NP-40, 10 mM MgCl 2 , 1 mM EDTA, 10% glycerol, 1 mM DTT and protease inhibitor cocktail. Total protein concentration was determined using a Bradford colorimetric assay.
Erastin A6 and B2 were dissolved in DMSO at 10 mg ml -1
. 100 ml AffiGel-10 (BioRad) was washed and resuspended in 400 ml DMSO. 10 ml compound and 3 ml 1:100 dilution of triethylamine in DMSO were added. The suspension was incubated at room temperature for 14 h, washed (1 ml per wash) five times in DMSO, three times in PBS, resuspended in 3 M ethanolamine in PBS, incubated 1 h at room temperature, washed five times in PBS and resuspended in 200 ml PBS. For the pull-down experiments, 50 ml of the A6 or B2 gel slurry were washed with binding buffer (0.1 M KCl, 20 mM HEPES (pH 7.6), 0.1 mM EDTA, 10% glycerol, 0.1% NP-40, 1 mM DTT, 0.25 mM phenylmethylsulphonyl fluoride) and incubated with 1 ml cell lysate (2 mg ml -1 for 1.5 h at 4 uC), washed with binding buffer, washed three times with high salt buffer (0.35 M KCl, 20 mM HEPES (pH 7.6), 0.1 mM EDTA, 10% glycerol, 0.1% NP-40, 1 mM DTT, 0.25 mM phenylmethylsulphonyl fluoride), washed with binding buffer, and eluted twice with 50 ml elution buffer (binding buffer with 0.8% N-lauroyl sarkosine). Proteins from the supernatant were precipitated with 400 ml ethanol, sedimented by centrifugation (16,800g) and digested as described 23 . Reverse-phase high-performance liquid chromatography was performed using a nano LC system (Dionex): a 75 mm 3 150 mm column, a Famos autosampler, a Switchos II system and an UltiMate binary pumping module. Samples were analysed using both a 4700 Proteomics Analyser MALDI-TOF/TOF (TOF/TOF; Applied Biosystems) and a Q Trap (AB/MDS Sciex), and the peptide level data were combined. To construct the databases used for protein identification, the following steps were performed: the NCBInr protein sequence FASTA file was downloaded, the GI numbers (sequence version identification) were updated, and the missing or incorrectly annotated taxonomies were fixed by referencing them to the NCBI taxonomy index (index of GI number versus species). The human subset of proteins in the database was extracted into a separate database (HumanNR). All protein sequences in HumanNR were matched to the corresponding protein in RefSeq using BLAST 25 . MS/MS data obtained from the TOF/ TOF and Q Trap were searched using Mascot (Matrix Sciences, London, UK). All searches were performed against either the corrected NCBInr protein sequence database or the HumanNR database. GPS Explorer (Applied Biosystems) was used for submitting data acquired from the TOF/TOF for database searching. The Mascot-based search was performed using the default settings for the specific instrument type as supplied by Matrix Science, except that ions with scores below ten were excluded from the results.
The spectra of the peptides identified in the automatic data analysis were manually inspected for the quality of the corresponding spectra and for consistency with the obtained results. Only high quality spectra and results with a peptide score of 20 or higher were accepted and used for the identification of proteins. Transmission electron microscopy of BJ-TERT/LT/ST/RAS V12 cells treated with erastin. Cells were incubated for 10 h in the presence of erastin (20 mg ml -1
